- SAF-189s in previously treated patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC): Results from the dose-finding portion in a single-arm, first-in-human phase I/II study.Yang, Jin-Ji; Zhou, Jianying; Yang, Nong; Wu, Zhuli; Sun, Juan; Hui, Ai-Min; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2020-05-29 To 2020-05-31.被引 3
- ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)Solomon, B. J.; Ahn, J. S.; Dziadziuszko, R.; Barlesi, F.; Nishio, M.; Lee, D. H.; Lee, J. S.; Zhong, W. Z.; Horinouchi, H.; Mao, W.; Hochmair, M. J.; De Marinis, F.; Migliorino, M. R.; Bondarenko, I.; Lohmann, T. O.; Xu, T.; Gavaldon, A. Cardona; Bordogna, W.; Ruf, T.; Wu, Y. L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.被引 3
- CtDNA dynamic detection reflects the clinical efficacy following treatment in NSCLC patients.Feng, Wei-Neng; Gu, Weiguang; Zhang, Hua; Lu, Yiyu; Gu, Weiquan; Li, Minjing; Yang, Shuang; Ye, Zhijian; Liu, Jian; Lin, Qing; Liang, Yaojun; Chen, Haiming; Shi, Xiaoliang; You, DongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
会议论文
ctDNA analysis of SAF-189s efficacy in ALK plus advanced nonsmall cell lung cancer (NSCLC)
12阅读
